Physician Views: Oncologist response to Radius, Menarini’s new SERD data

We are snap-polling oncologists to gauge reaction to detailed results from the Phase III EMERALD study evaluating Radius Heath and Menarini’s oral SERD elacestrant for the treatment of ER-positive/HER2-negative breast cancer, which were presented this week at the San Antonia Breast Cancer Symposium (SABCS).

The results for elacestrant are notable as they pre-empt the readout of pivotal-stage data from similar studies for oral SERDs being developed by larger players in AstraZeneca, Roche and Sanofi next year.

Specifically we are asking oncologists

  • How the progression free survival (PFS) efficacy data for elacestrant compare to current standard of care
  • How the safety/tolerability profile of elacestrant compares to its demonstrated efficacy
  • Perception of overall (efficacy and safety) data for elacestrant and potential impact on treatment practice
  • If elacestrant was approved now and was reimbursable their comfort level prescribing it to eligible patients as per the EMERALD study design
  • If elacestrant was approved now and was reimbursable their comfort level prescribing it to eligible patients with ESR1-mutated tumors

Notify me of the results

Poll results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers.

To read more Physician Views articles, click here.